Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem?s Approval & More
Xconomy
MAY 29, 2020
ASCO 2020 won’t be the Windy City gathering it usually is, but drug and diagnostics developers are still raring to share fresh data from their efforts in cancer immunotherapy, targeted treatments, and early-stage screening methods during the course of the three-day scientific program. While oncology.
Let's personalize your content